Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer

Xianhui Su; Xuewen Sun; Ying Wang; Yanhui Kang; Yuna Dai

doi:10.12669/pjms.38.6.5287

Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer

Pak J Med Sci. 2022 Jul-Aug;38(6):1508-1513. doi: 10.12669/pjms.38.6.5287.

Authors

Xianhui Su¹, Xuewen Sun², Ying Wang³, Yanhui Kang⁴, Yuna Dai⁵

Affiliations

¹ Xianhui Su, Department of Pharmacology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
² Xuewen Sun, Department of Pathogenic Biology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
³ Ying Wang, Department of Pharmacology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
⁴ Yanhui Kang, Department of Pharmacology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
⁵ Yuna Dai, Department of Breast Surgery, Affiliated Hospital of Hebei Engineering University, Handan 056029, Hebei, China.

Abstract

Objectives: To investigate the clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on the levels of antigen cluster protein 133 (CD133) and human epididymal secretory protein 4 (HE4) in patients with advanced epithelial ovarian cancer (EOC).

Methods: A total of 104 patients with advanced EOC hospitalized in Affiliated Hospital of Hebei Engineering University from April 2015 to December 2018 were assigned to two groups using a random number table. A control group (n =52) treated by the conventional postoperative TP regimen and an observation group (n =52) receiving HIPEC in addition to the conventional postoperative TP regimen. CD133 and HE4 expression in serum, overall response rate (ORR), long-term efficacy, and incidence of drug toxicity were measured for comparative analysis.

Results: The serum levels of CD133 and HE4 expression in the observation group were lower than in the control group (P < 0.005, respectively); the observation group surpassed the control group in ORR, 2-year survival, and progression-free survival (PFS) (P < 0.005, respectively); however, the two groups had no statistically significant difference in the incidence of drug toxicity (P > 0.05).

Conclusions: TP-based HIPEC can effectively inhibit CD133 and HE4 expression in advanced EOC, which thereby improves the clinical efficacy and encourages longer survival.

Keywords: Advanced epithelial ovarian cancer; Antigen cluster protein 133 (CD133); Human epididymal secretory protein 4 (HE4); Intraperitoneal chemotherapy; TP regimen.